Urovant Sciences (UROV) Tops Q1 EPS by 40c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Urovant Sciences Reports Fiscal First Quarter 2020 Results
August 13, 2020 4:05 PM EDTIRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)-- Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months ended June 30, 2020.
The first quarter of fiscal 2020 saw the Company achieve a number of significant operational milestones as it embarked on the build out of both its commercial and market access teams and completed enrollment in the Phase 2a study of vibegron for irritable bowel syndrome (IBS) pain.
We continued to make important progress in the first fiscal quarter of 2020. We significantly enhanced the commercial and market access capabilities we need to successfully... More
